Mary Mader, PhD

Chemist

Dr. Mary Mader is an accomplished medicinal chemist with a career spanning pharmaceutical, biotech, and not-for-profit drug discovery.  During her time at Eli Lilly and Company and Relay Therapeuticshe, she contributed to the development of multiple clinical candidates in oncology, with a focus on kinase and epigenetic targets,.

Mary earned her Ph.D. in Organic Chemistry from the University of Notre Dame and completed an NIH postdoctoral fellowship at the University of California, Berkeley. She has held key leadership roles in the scientific community, including chairing the Medicinal Chemistry Gordon Research Conference and the inaugural Gordon Research Seminar.

She currently serves on the editorial board of Molecular Cancer Therapeutics and on advisory committees for the AACR and the Medicines for Malaria Venture. Mary is recognized for her deep scientific insight and collaborative approach to advancing drug discovery.